Understand the source comparison
Comparison: Cartalax vs Other Vascular Peptides
Cartalax (Ala-Glu) Genomic regulation of endothelial cytoprotective genes hTERT upregulation 1.9-fold in senescent cells SOD +65%, catalase +48% within 72 hours Vascular endothelium (arterial > venous) Best-documented peptide for endothelial replicative lifesp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cartalax (Ala-Glu)
- Genomic regulation of endothelial cytoprotective genes
- hTERT upregulation 1.9-fold in senescent cells
- SOD +65%, catalase +48% within 72 hours
- Vascular endothelium (arterial > venous)
- Best-documented peptide for endothelial replicative lifespan extension. Mechanism is well-mapped, effect persists post-treatment
- Epithalon (Ala-Glu-Asp-Gly)
- Pineal gland melatonin pathway modulation + telomerase activation
- Broader hTERT upregulation across multiple tissues
- Indirect. Via circadian rhythm normalisation
- Pineal, hypothalamus, some peripheral tissues
- Stronger telomerase activator but less endothelial-specific. Overlap with Cartalax on telomeric effects
- Thymalin (thymic peptide extract)
- T-cell differentiation and immune checkpoint regulation
- No direct telomerase effect documented
- Minimal. Primarily immunomodulatory
- Thymus, T-lymphocytes
- No vascular selectivity. Immune function tool, not vascular cytoprotection
- Vilon (Lys-Glu)
- Similar genomic regulation mechanism to Cartalax
- Modest hTERT effect (1.3-fold)
- SOD +38%, lower magnitude than Cartalax
- Thymus, some endothelial effect
- Less potent endothelial regulator. Used primarily in immune senescence contexts
- BPC-157 (synthetic peptide)
- Angiogenesis via VEGF pathway upregulation, no genomic mechanism
- None. Operates through growth factor signalling
- None. Mechanism is pro-angiogenic, not antioxidant
- Broad. GI tract, tendons, vascular tissue
- Complementary to Cartalax but mechanistically distinct. Promotes vessel growth, does not extend cell lifespan
- Cartalax stands alone in its combination of endothelial-specific genomic regulation, measurable telomerase reactivation, and persistent antioxidant enzyme upregulation. BPC-157 promotes angiogenesis but does not address oxidative damage or replicative senescence. Epithalon overlaps significantly with Cartalax on telomerase but lacks the same degree of vascular tissue specificity. For researchers focused on endothelial aging and vascular health span, Cartalax remains the most targeted peptide tool available.